Q-omics provides the consensus-scored SMG1P4 profile across patient tissues and cancer cell-line models. SMG1P4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SMG1P4 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, SMG1P4 RNA expression shows 6,887 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight OV, KIRC, and KIRP as cancer lineages where SMG1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMG1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMG1P4 survival associations across molecular data types. SMG1P4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMG1P4 RNA expression–survival associations across cancer types. High SMG1P4 expression shows unfavorable associations in MESO, COAD, LUSC and LGG, but favorable associations in OV and KIRC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for SMG1P4 RNA expression.
This table summarizes SMG1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMG1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMG1P4 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher SMG1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .004).
This table shows molecular features associated with SMG1P4 in patient tissues and cancer cell lines. In patient samples, SMG1P4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
